Literature DB >> 34267351

Neutralizing shapeshifting pericytes enhances glioblastoma therapeutic efficacy.

Samuel A Sprowls1,2, Justin D Lathia3,4,5.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 34267351      PMCID: PMC8486815          DOI: 10.1038/s41422-021-00538-1

Source DB:  PubMed          Journal:  Cell Res        ISSN: 1001-0602            Impact factor:   46.297


× No keyword cloud information.
  9 in total

Review 1.  Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology.

Authors:  Xuanmao Jiao; Omar Nawab; Tejal Patel; Andrew V Kossenkov; Niels Halama; Dirk Jaeger; Richard G Pestell
Journal:  Cancer Res       Date:  2019-07-10       Impact factor: 12.701

2.  Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.

Authors:  Michael Weller; Nicholas Butowski; David D Tran; Lawrence D Recht; Michael Lim; Hal Hirte; Lynn Ashby; Laszlo Mechtler; Samuel A Goldlust; Fabio Iwamoto; Jan Drappatz; Donald M O'Rourke; Mark Wong; Mark G Hamilton; Gaetano Finocchiaro; James Perry; Wolfgang Wick; Jennifer Green; Yi He; Christopher D Turner; Michael J Yellin; Tibor Keler; Thomas A Davis; Roger Stupp; John H Sampson
Journal:  Lancet Oncol       Date:  2017-08-23       Impact factor: 41.316

3.  Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth.

Authors:  Lin Cheng; Zhi Huang; Wenchao Zhou; Qiulian Wu; Shannon Donnola; James K Liu; Xiaoguang Fang; Andrew E Sloan; Yubin Mao; Justin D Lathia; Wang Min; Roger E McLendon; Jeremy N Rich; Shideng Bao
Journal:  Cell       Date:  2013-03-28       Impact factor: 41.582

4.  CCL5 of glioma-associated microglia/macrophages regulates glioma migration and invasion via calcium-dependent matrix metalloproteinase 2.

Authors:  Caren Yu-Ju Wu; Chia-Hua Chen; Chun-Yen Lin; Li-Ying Feng; Yung-Chang Lin; Kuo-Chen Wei; Chiung-Yin Huang; Jia-You Fang; Pin-Yuan Chen
Journal:  Neuro Oncol       Date:  2020-02-20       Impact factor: 12.300

5.  Targeting Glioma Stem Cell-Derived Pericytes Disrupts the Blood-Tumor Barrier and Improves Chemotherapeutic Efficacy.

Authors:  Wenchao Zhou; Cong Chen; Yu Shi; Qiulian Wu; Ryan C Gimple; Xiaoguang Fang; Zhi Huang; Kui Zhai; Susan Q Ke; Yi-Fang Ping; Hua Feng; Jeremy N Rich; Jennifer S Yu; Shideng Bao; Xiu-Wu Bian
Journal:  Cell Stem Cell       Date:  2017-11-02       Impact factor: 24.633

Review 6.  Modulation of the chemokine/chemokine receptor axis as a novel approach for glioma therapy.

Authors:  Gregory P Takacs; Joseph A Flores-Toro; Jeffrey K Harrison
Journal:  Pharmacol Ther       Date:  2020-12-11       Impact factor: 12.310

Review 7.  Cancer stem cells in glioblastoma.

Authors:  Justin D Lathia; Stephen C Mack; Erin E Mulkearns-Hubert; Claudia L L Valentim; Jeremy N Rich
Journal:  Genes Dev       Date:  2015-06-15       Impact factor: 11.361

8.  Upregulated functional gene expression programmes in tumour pericytes mark progression in patients with low-grade glioma.

Authors:  Clara Oudenaarden; Jonas Sjölund; Kristian Pietras
Journal:  Mol Oncol       Date:  2021-06-05       Impact factor: 6.603

9.  Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling.

Authors:  Xiao-Ning Zhang; Kai-Di Yang; Cong Chen; Zhi-Cheng He; Qiang-Hu Wang; Hua Feng; Sheng-Qing Lv; Yan Wang; Min Mao; Qing Liu; Yao-Yao Tan; Wen-Ying Wang; Tian-Ran Li; Lin-Rong Che; Zhong-Yi Qin; Ling-Xiang Wu; Min Luo; Chun-Hua Luo; Yu-Qi Liu; Wen Yin; Chao Wang; Hai-Tao Guo; Qing-Rui Li; Bin Wang; Wei Chen; Shuang Wang; Yu Shi; Xiu-Wu Bian; Yi-Fang Ping
Journal:  Cell Res       Date:  2021-07-08       Impact factor: 25.617

  9 in total
  1 in total

1.  Network Pharmacology and Inflammatory Microenvironment Strategy Approach to Finding the Potential Target of Siraitia grosvenorii (Luo Han Guo) for Glioblastoma.

Authors:  Juan Li; Xin Zhang; Yunpeng Cao; Kun Lv; Lan Jiang
Journal:  Front Genet       Date:  2021-12-20       Impact factor: 4.599

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.